Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma

Oncotarget

Volumn 6, Issue 10, 2015, Pages 7408-7423

  Molejon, Maria Inés ^a   Tellechea, Juan Ignacio ^a,b   Loncle, Celine ^a   Gayet, Odile ^a   Gilabert, Marine ^a   Duconseil, Pauline ^a   Lopez Millan, Maria Belen ^a   Moutardier, Vincent ^a,b   Gasmi, Mohamed ^a,b   Garcia, Stephane ^a,b   Turrini, Olivier ^a,c   Ouaissi, Mehdi ^d   Poizat, Flora ^c   Dusetti, Nelson ^a   Iovanna, Juan ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL NORD   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

CD44; Pancreas cancer; Recurrence; Xenograft

Indexed keywords

DOCETAXEL; FIRTECAN; FLUOROURACIL; GEMCITABINE; HERMES ANTIGEN; MUCIN 1; OXALIPLATIN; TRANSCRIPTION FACTOR ZEB1; CD44 PROTEIN, HUMAN; DEOXYCYTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RECURRENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENETIC TRANSFORMATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PHENOTYPE; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; CELL GROWTH; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; RECURRENT DISEASE; TUMOR RECURRENCE;

ANIMALS; ANTIGENS, CD44; CARCINOMA, PANCREATIC DUCTAL; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; DEOXYCYTIDINE; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; RECURRENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928383798     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3510     Document Type: Article

References (43)

1. Paulson AS, Tran Cao HS, Tempero MA and Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013; 144(6):1316-1326.
2. Hidalgo M. Pancreatic cancer. The New England journal of medicine. 2010; 362(17):1605-1617.
3. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM and Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut. 2011; 60(6):861-868.
4. Hung SW, Mody HR and Govindarajan R. Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer letters. 2012; 320(2):138-149.
5. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(33):5513-5518.
6. Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, Trouilloud I, Malka D, Bachet JB, Coriat R, Terrebonne E, De La Fouchardiere C, Manfredi S, Solub D, Lecaille C, Thirot Bidault A, et al. FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort. Annals of surgical oncology. 2014.
7. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine. 2011; 364(19):1817-1825.
8. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ and Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell stem cell. 2007; 1(3):313-323.
9. Reya T, Morrison SJ, Clarke MF and Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-111.
10. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66(19):9339-9344.
11. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3):1030-1037.
12. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP and Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell stem cell. 2007; 1(4):389-402.
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(7):3983-3988.
14. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65(23):10946-10951.
15. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, Clarke MF, Hoey T, Lewicki J and Gurney AL. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One. 2008; 3(6):e2428.
16. Pattabiraman DR and Weinberg RA. Tackling the cancer stem cells-what challenges do they pose? Nat Rev Drug Discov. 2014; 13(7):497-512.
17. Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N, Validire P, Dutrillaux B, Praz F, Bellet D and Poupon MF. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 2007; 67(1):398-407.
18. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K and Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res. 2005; 65(14):6207-6219.
19. Ho MM, Ng AV, Lam S and Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007; 67(10):4827-4833.
20. Liu J, Xiao Z, Wong SK, Tin VP, Ho KY, Wang J, Sham MH and Wong MP. Lung cancer tumorigenicity and drug resistance are maintained through ALDH(hi)CD44(hi) tumor initiating cells. Oncotarget. 2013; 4(10):1698-1711.
21. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B and Menendez JA. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 2012; 3(4):395-398.
22. Hutas G, Bajnok E, Gal I, Finnegan A, Glant TT and Mikecz K. CD44-specific antibody treatment and CD44 deficiency exert distinct effects on leukocyte recruitment in experimental arthritis. Blood. 2008; 112(13):4999-5006.
23. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R and Eger A. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 2007; 26(49):6979-6988.
24. Vila MR, Balague C and Real FX. Cytokeratins and mucins as molecular markers of cell differentiation and neoplastic transformation in the exocrine pancreas. Zentralblatt fur Pathologie. 1994; 140(3):225-235.
25. Gatti M, Pattarozzi A, Bajetto A, Wurth R, Daga A, Fiaschi P, Zona G, Florio T and Barbieri F. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology. 2013; 314(2-3):209-220.
26. Wei W, Tweardy DJ, Zhang M, Zhang X, Landua J, Petrovic I, Bu W, Roarty K, Hilsenbeck SG, Rosen JM and Lewis MT. STAT3 Signaling Is Activated Preferentially in Tumor-Initiating Cells in Claudin-Low Models of Human Breast Cancer. Stem cells. 2014; 32(10):2571-2582.
27. Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, Simeone DM, Zou W and Welling TH. Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells. Gastroenterology. 2014.
28. Watanabe Y, Yoshimura K, Yoshikawa K, Tsunedomi R, Shindo Y, Matsukuma S, Maeda N, Kanekiyo S, Suzuki N, Kuramasu A, Sonoda K, Tamada K, Kobayashi S, Saya H, Hazama S and Oka M. A stem cell medium containing neural stimulating factor induces a pancreatic cancer stemlike cell-enriched population. International journal of oncology. 2014; 45(5):1857-1866.
29. Feng Y, Dai X, Li X, Wang H, Liu J, Zhang J, Du Y and Xia L. EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis. Cell proliferation. 2012; 45(5):413-419.
30. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nature reviews Cancer. 2011; 11(4):254-267.
31. Louderbough JM, Brown JA, Nagle RB and Schroeder JA. CD44 Promotes Epithelial Mammary Gland Development and Exhibits Altered Localization during Cancer Progression. Genes & cancer. 2011; 2(8):771-781.
32. Li L, Hao X, Qin J, Tang W, He F, Smith A, Zhang M, Simeone DM, Qiao XT, Chen ZN, Lawrence TS and Xu L. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology. 2014; 146(4):1108-1118.
33. D'Arena G, Calapai G and Deaglio S. Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498. Expert opinion on therapeutic patents. 2014; 24(7):821-828.
34. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S and Kipps TJ. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(15):6127-6132.
35. Visvader JE and Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature reviews Cancer. 2008; 8(10):755-768.
36. Visvader JE and Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell stem cell. 2012; 10(6):717-728.
37. Malaney P, Nicosia SV and Dave V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer letters. 2014; 344(1):1-12.
38. Fuso Nerini I, Morosi L, Zucchetti M, Ballerini A, Giavazzi R and D'Incalci M. Intratumor heterogeneity and its impact on drug distribution and sensitivity. Clinical pharmacology and therapeutics. 2014; 96(2):224-238.
39. Navin NE. Tumor evolution in response to chemotherapy: phenotype versus genotype. Cell reports. 2014; 6(3):417-419.
40. Brambilla E, Moro D, Gazzeri S, Brichon PY, Nagy-Mignotte H, Morel F, Jacrot M and Brambilla C. Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1991; 9(1):50-61.
41. Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nature reviews Cancer. 2002; 2(3):221-225.
42. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell cycle. 2005; 4(12):1693-1698.
43. Schreiber FS, Deramaudt TB, Brunner TB, Boretti MI, Gooch KJ, Stoffers DA, Bernhard EJ and Rustgi AK. Successful growth and characterization of mouse pancreatic ductal cells: functional properties of the Ki-RAS(G12V) oncogene. Gastroenterology. 2004; 127(1):250-260.